Relating to participation in federal prescription drug pricing programs.
Summary
House Bill 5553 would authorize the West Virginia Public Employees Insurance Agency (PEIA), the Department of Human Services, and other state agencies that administer health benefit programs to participate in federal prescription drug pricing programs, including arrangements based on most-favored-nation or international reference pricing models, if permitted by federal law. The bill allows these agencies to use direct purchasing agreements, federally negotiated pricing arrangements, or federal benchmark or ceiling prices for prescription drugs.
The measure makes participation voluntary and conditions it on the agency determining that it is in the state’s financial interest and will not reduce access to medically necessary drugs. It also preserves state control over pharmacy benefit administration and states that the bill should not be read to require a federal formulary or to conflict with federal Medicaid rules or waivers. Each affected agency would have to report annually to the Joint Committee on Government and Finance on participation, savings, and any access or administrative issues.
Impact
The bill would amend PEIA’s existing authority to take advantage of federal acts and grants, and it would add a new section to the Human Services code authorizing participation in federal prescription drug pricing programs. In practical terms, it expands state law to explicitly permit state health programs to seek lower drug costs through federal pricing mechanisms, while leaving implementation discretionary and subject to federal law. It could affect PEIA, Medicaid-related programs, and other state-administered health benefit plans that purchase prescription drugs, potentially changing how they negotiate, reimburse, or purchase medications.
Sentiment
The bill’s stated purpose and structure suggest generally favorable sentiment toward using federal pricing tools to reduce prescription drug costs and generate savings for the state. Because there is no committee transcript or recorded vote history provided, there is no direct evidence of opposition or support from lawmakers in the available materials. The bill’s emphasis on voluntariness, financial benefit, and preserving access indicates an effort to make the proposal broadly acceptable and to address likely concerns in advance.
Contention
The main points of potential contention are whether federal pricing models such as most-favored-nation or international reference pricing are appropriate or workable for state programs, and whether participation could affect beneficiary access to needed medications. Another possible concern is administrative complexity and the extent to which federal requirements, Medicaid waivers, or pharmacy benefit rules might limit implementation. The bill anticipates these objections by making participation optional, preserving state authority over pharmacy benefits, and requiring annual reporting on savings and any access problems.
An Act amending the act of May 13, 2008 (P.L.139, No.14), known as the Cancer Drug Repository Program Act, further providing for title and short title of act, for definitions, for establishment, for r . . .estocking and dispensing of cancer drugs, for storage, distribution and fees and for immunity; providing for annual report, for list of approved participating pharmacies and for limitations; further providing for regulations; and imposing duties on the State Board of Pharmacy.
Establishes a state-run prescription drug purchasing pool, available for participation by nonstate public employers, private employers, and health insurance carriers, to maximize the value of drug discounts available to participants.
Establishes a state-run prescription drug purchasing pool, available for participation by nonstate public employers, private employers, and health insurance carriers, to maximize the value of drug discounts available to participants.